

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shenzhen Edge Medical Co., Ltd.**

**深圳市精鋒醫療科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2675)**

## **VOLUNTARY ANNOUNCEMENT INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE**

This announcement is made by Shenzhen Edge Medical Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest developments of the Group.

The board of directors of the Company (the “**Board**”) wishes to announce that it intends to exercise its powers under the general mandate (the “**Share Repurchase Mandate**”) given to the Board pursuant to the resolution of the shareholders of the Company (the “**Shareholders**”) passed at a general meeting of the Company held on June 16, 2025, to repurchase the H shares of the Company (the “**H Shares**”). The Board has decided to utilize the Share Repurchase Mandate up to HK\$200 million to repurchase H Shares in the open market from time to time, subject to market conditions (the “**Proposed Share Repurchase**”).

Pursuant to the Share Repurchase Mandate, the number of H Shares to be repurchased shall not exceed 10% of the total number of the H Shares in issue as at the date of the Company’s listing on The Stock Exchange of Hong Kong Limited (excluding any treasury shares).

The implementation period of the Proposed Share Repurchase is until the expiration of the earliest of: (i) the conclusion of the next annual general meeting of the Company at which time it shall lapse; or (ii) the revocation or variation of the Share Repurchase Mandate by a special resolution at any general meeting of the Company.

The Company will conduct the Proposed Share Repurchase in compliance with the articles of association of the Company, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, the Codes on Takeovers and Mergers and Share Buy-backs, the Company Law of the People’s Republic of China (《中華人民共和國公司法》) and all applicable laws and regulations to which the Company is subject.

The Board believes that a share repurchase in the present conditions will demonstrate the Company's confidence in its own business outlook and prospects, further safeguard the rights and interests of the Shareholders and enhance the investors' confidence, which will ultimately benefit the Company and create value for the Shareholders. The Board also believes that the current financial resources of the Company would enable it to implement the Proposed Share Repurchase while maintaining a solid financial position.

**Shareholders and potential investors should note that any repurchase may be done subject to market conditions and any regulatory procedures and/or approvals that may be required for any repurchase, and at the Board's absolute discretion. There is no assurance of whether any repurchase may be done, and the timing, quantity or price of any repurchase. Shareholders and potential investors should therefore exercise caution when dealing in the H Shares.**

By order of the Board  
**Shenzhen Edge Medical Co., Ltd.**  
(深圳市精鋒醫療科技股份有限公司)

**Dr. Wang Jianchen**  
*Chairman of the Board and Executive Director*

Hong Kong, June 9, 2026

*As at the date of this announcement, the board of directors of the Company comprises (i) Dr. Wang Jianchen, Dr. Gao Yuanqian and Ms. Wu Mengyuan as executive directors; (ii) Mr. Sheng Li, Mr. Chen Gang and Mr. Qiu Xiang as non-executive directors, and (iii) Mr. Yang Fan, Mr. Zhang Guoguang and Mr. Lau Ying Kit as independent non-executive directors.*